Ludek P.
- Country
- Czechia
- Department
- N/A
Research Overview
Specializations
Cardiovascular Disease and Atherosclerosis
Investigation of risk reduction and therapeutic strategies for atherosclerotic cardiovascular disease across primary and secondary prevention settings.
- Major adverse cardiovascular events
- Lipid‑lowering therapies
- Lipoprotein(a) lowering agents
- Vascular inflammation modulation
Emphasis on integrating novel agents with guideline‑based care to improve long‑term outcomes.
Heart Failure and Cardiac Amyloidosis
Targeted research on therapeutic options for patients with heart failure, including reduced and preserved ejection fraction phenotypes, and transthyretin amyloid cardiomyopathy.
- Combination diuretic and SGLT2 inhibitor regimens
- Myocardial stress biomarker modulation
- Agent‑specific effects on cardiac remodeling
- Quality‑of‑life improvement in HFpEF/HFrEF
Focus on disease‑modifying approaches that address both hemodynamic and metabolic contributors.
Metabolic Disorders: Diabetes and Obesity
Clinical exploration of interventions for type 2 diabetes and excess body weight, aiming to achieve glycaemic control and weight reduction.
- Glucose‑dependent insulinotropic therapies
- Weight‑loss agents combined with insulin analogues
- Metabolic syndrome risk factor optimization
- Impact on cardiovascular risk profiles
Integration of metabolic endpoints with cardiovascular safety assessments.
Dyslipidemia and Lipoprotein(a) Management
Focused studies on severe hypertriglyceridemia, hypercholesterolemia, and elevated lipoprotein(a) levels to mitigate atherogenic risk.
- Triglyceride‑lowering RNA therapeutics
- PCSK9 inhibition and LDL‑C reduction
- Novel antisense oligonucleotides targeting Lp(a)
- Combination lipid‑modifying regimens
Strategic targeting of lipid pathways to complement standard statin therapy.
Renal and Pulmonary Comorbidities
Evaluation of therapeutic approaches for chronic kidney disease and chronic obstructive pulmonary disease in the context of cardiovascular risk.
- Renal‑protective effects of SGLT2 inhibitors
- Blood‑pressure control in resistant hypertension
- Exacerbation reduction strategies in COPD
- Inflammatory pathway modulation in CKD
Addressing multi‑organ disease interplay to improve overall patient prognosis.
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.